Menu
Ulf Bladin is a Bachelor of Medicine from Karolinska Institutet, holds a Master of Business Administration and an MSc from the Stockholm School of Economics. Ulf has previously been General Manager, Vice President of the EMEA region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, and Vice President with Global Responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia. He has also held leading commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dohme. Board member of Lumito AB.
Shareholding as of 04/11/2024:
6,932,209 shares, 1,000,000 warrants through incentive program.
Education and background: Henrik Ljung has a master’s degree in economics from Lund University. He has a solid background as a chartered accountant and many years of experience as a CFO in listed companies, such as Acconeer AB, Carbiotix AB and Qlife Holding AB, and AB Sardus. Henrik has extensive experience of companies in an early stage of development, as well as company acquisitions.
Shareholding as of 04/11/2024:
670,568 shares.
Education and Background: Karl holds a Bachelor of Engineering from the University of Greenwich. Karl has a proven track record within operational leadership roles having a wide range of experience in regulated manufacturing encompassing aerospace, medical devices and pharmaceuticals. Karl previously held the position of Head of Operations for Swedish contract pharmaceutical manufacturer Recipharm and has also held manufacturing leadership roles at defence giant BAE Systems and medical science company Olympus. Karl has a strong knowledge of lean principles and operational excellence that has been used to develop high performing teams and effective processes that deliver results.
Shareholding as of 04/11/2024:
4,050,000 shares, 2,000,000 warrants through incentive program.
Education and Background: Karl holds a Bachelor of Engineering from the University of Greenwich. Karl has a proven track record within operational leadership roles having a wide range of experience in regulated manufacturing encompassing aerospace, medical devices and pharmaceuticals. Karl previously held the position of Head of Operations for Swedish contract pharmaceutical manufacturer Recipharm and has also held manufacturing leadership roles at defence giant BAE Systems and medical science company Olympus. Karl has a strong knowledge of lean principles and operational excellence that has been used to develop high performing teams and effective processes that deliver results.
Shareholding as of 04/11/2024:
4,050,000 shares, 2,000,000 warrants through incentive program.
Education and background: PhD in biochemistry and genetics at Oxford University followed by Postdoctoral Research Fellowships at Oxford and the Joslin Diabetes Center, Boston USA (affiliated to Harvard Medical School) researching the genetics of Type 2 diabetes.
Aileen McGettrick is co-founder of Psyros and has 15 years of experience in assay development for medical devices. From 2008 to 2018 in her role as Group Head of Assay Development she led multi-disciplinary teams for VC backed start-up Vivacta Ltd and subsequently the Novartis Near Patient Testing Unit (after acquisition of Vivacta by Novartis in 2012), specializing in detection of target analytes in whole blood for point of care diagnostics. With a broad working knowledge of the regulatory requirements for medical devices she brings strong operational and project management skills to the team.
Shareholding as of 04/11/2024:
31,505,100 shares.
Education and background: Steve Ross has two undergraduate degrees, one in chemistry, the other in mathematics with statistics, and he received his PhD from Edinburgh University in synthetic chemistry. He subsequently carried out postdoctoral research at The University of Utah (Royal Society Fellowship), the CNRS in Toulouse, France (Marie Curie Fellowship) and The University of Oxford.
Steve Ross is a co-founder of Psyros and has worked in in-vitro diagnostics for over 15 years. His industrial career started in 2001 with PiezOptic, developing pyroelectric sensors for monitoring exposure to toxic gases. In 2006 he co-founded Vivacta, a start-up company using the same pyroelectric technology, this time for point-of-care clinical diagnostics.
Shareholding as of 04/11/2024:
31,505,100 shares.
Education and background:
PhD in microfluidic lab-on-a-chip devices from Imperial College, London. This was followed by a postdoctoral research post at the University of Glasgow, developing lab-on-a-chip devices for IVD applications.
Paul is a co-founder of Psyros. With over 20 years of IVD development experience, he brings a wide breadth of knowledge of point-of-care device development, including both technical and regulatory aspects. Prior to Psyros, Paul led the system development team at the VC-funded start-up Vivacta ltd., where he oversaw system development from early concept through to the Niji point-of-care platform. Vivacta was acquired by Novartis Pharmaceuticals in 2012 and the Niji platform was CE-marked in 2016. In his current role, Paul oversees development of the Psyros analyser and test cartridge.
Shareholding as of 04/11/2024:
31,505,100 shares.
Shareholding as of 04/11/2024:
2,250,000 shares, 1,000,000 warrants through incentive program
Education and background: Andrew studied Engineering though the Open University and has more than 20 years’ experience in the design, development, and manufacture of medical and in-vitro diagnostics devices, with expertise in international quality management systems and regulatory requirements. Previous positions include Quality Assurance and Regulatory Affairs Manager at Integrated Technologies Ltd and subsequently Advanced Healthcare Ltd.
Andrew’s expertise is in the effective integration of medical and IVD design and manufacture into a controlled and compliant environment, including ISO 13485 and FDA 21CFR Part 820, and satisfying international regulations such as the 2017/746 In-vitro Diagnostics Regulation.
Shareholding as of 31/03/2024:
800,000 warrants through incentive program.
Education and background: PhD in Biochemistry and an MBA from INSEAD. Over the last decades, Volker has strongly contributed to the development of point-of-care for heart disease but also in other disease areas. At Biosite, he led the international development of the Triage platform and launched the cardiac panel and the very first reimbursable BNP assay in Europe. Responsible for the launch of Quo-Test HbA1c at Quotient Diagnostics and participated in the reverse acquisition that later became EKF Diagnostics. Volker gained further insight into the POC business while working at Cholestech, Alere and more recently at Expand Healthcare Consulting GmbH, where he was a high-level advisor to private companies and non-profit organizations. He has also been the responsible manager of the healthcare R&D group at SK Telecom (now Invites Healthcare).
Chairman of the Board of Expand Healthcare Consulting GmbH and member of the Board of Ominilabs.
Shareholding as of 30/06/2023:
1 111 346 shares, 1,000,000 warrants through incentive program.
Education and background: PhD in Pure and Applied Biochemistry at Lund University. Solid experience from research, medicine, medtech and the biotechnology sectors. Solid entrepreneurial experience (e.g. Prolight Diagnostics AB, Lumito AB and Gasporox AB) and an expert in applied medicine, microbiology and biotech, especially in the development of different types of biomolecules for commercial use and research in biological applications. Board member in both medtech companies and other companies. Engaged in Prolight Diagnostics since 1999, and founder of the company.
Shareholding as of 04/11/2024:
11,406,812 shares through the Cardeon group in which Masoud owns 34,82% of the shares. 357,140 privately owned shares.
Education and background: Bachelor’s Degree in Chemistry and Biology from Uppsala University and a Master of Science from the University of North Carolina. 30 years of experience in the life science and diagnostics field. Worked in senior positions with a focus on marketing in international diagnostics companies such as Pharmacia Diagnostics, Boehringer Mannheim, Roche Scandinavia, Phadia and Thermo Fisher Scientific. Board member of Biovica AB. CEO of Prolight Diagnostics AB between 2016-2020.
Shareholding as of 04/11/2024:
1,264,914 shares, 361,404 warrants through incentive program.
Ulf Bladin is a Bachelor of Medicine from Karolinska Institutet, holds a Master of Business Administration and an MSc from the Stockholm School of Economics. Ulf has previously been General Manager, Vice President of the EMEA region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, and Vice President with Global Responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia. He has also held leading commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dohme. Board member of Lumito AB.
Shareholding as of 04/11/2024:
6,932,209 shares, 1,000,000 warrants through incentive program.
Education and background: Steve Ross has two undergraduate degrees, one in chemistry, the other in mathematics with statistics, and he received his PhD from Edinburgh University in synthetic chemistry. He subsequently carried out postdoctoral research at The University of Utah (Royal Society Fellowship), the CNRS in Toulouse, France (Marie Curie Fellowship) and The University of Oxford.
Steve Ross is a co-founder of Psyros and has worked in in-vitro diagnostics for over 15 years. His industrial career started in 2001 with PiezOptic, developing pyroelectric sensors for monitoring exposure to toxic gases. In 2006 he co-founded Vivacta, a start-up company using the same pyroelectric technology, this time for point-of-care clinical diagnostics.
Shareholding as of 04/11/2024:
31,505,100 shares.
Education and background: PhD in biochemistry and genetics at Oxford University followed by Postdoctoral Research Fellowships at Oxford and the Joslin Diabetes Center, Boston USA (affiliated to Harvard Medical School) researching the genetics of Type 2 diabetes.
Aileen McGettrick is co-founder of Psyros and has 15 years of experience in assay development for medical devices. From 2008 to 2018 in her role as Group Head of Assay Development she led multi-disciplinary teams for VC backed start-up Vivacta Ltd and subsequently the Novartis Near Patient Testing Unit (after acquisition of Vivacta by Novartis in 2012), specializing in detection of target analytes in whole blood for point of care diagnostics. With a broad working knowledge of the regulatory requirements for medical devices she brings strong operational and project management skills to the team.
Shareholding as of 04/11/2024:
31,505,100 shares.
Education and background: PhD in Biochemistry and an MBA from INSEAD. Over the last decades, Volker has strongly contributed to the development of point-of-care for heart disease but also in other disease areas. At Biosite, he led the international development of the Triage platform and launched the cardiac panel and the very first reimbursable BNP assay in Europe. Responsible for the launch of Quo-Test HbA1c at Quotient Diagnostics and participated in the reverse acquisition that later became EKF Diagnostics. Volker gained further insight into the POC business while working at Cholestech, Alere and more recently at Expand Healthcare Consulting GmbH, where he was a high-level advisor to private companies and non-profit organizations. He has also been the responsible manager of the healthcare R&D group at SK Telecom (now Invites Healthcare).
Chairman of the Board of Expand Healthcare Consulting GmbH and member of the Board of Ominilabs.
Shareholding as of 04/11/2024:
3,361,346 shares, 1,200,000 warrants through incentive program.
Kiarash Farr is a Master of Science in Engineering Physics from Royal Institute of Technology (KTH) Stockholm and Management Acceleration Program from INSEAD, Fontainebleau France. Kiarash is currently Senior Vice President of Commercial Operations at Boule Diagnostics. Kiarash has previously been Senior Director, Commercial Operations of the EMEA region at Hycor Biomedical, Sales Director Key account management at Thermo Fisher Scientific Immuno Diagnostics Division, and Business Director Asia at IBA with various leadership positions in Germany, China and India.
Shareholding as of 04/11/2024:
2,666,666 shares.
The nomination committee is appointed in consultation with the three largest shareholders or owner groups, according to the number of votes based on shareholder statistics from Euroclear Sweden, and other reliable owner information in accordance with the decision of the Annual General Meeting.
The nomination committee’s task is to produce proposals for the AGM regarding the chairman of the meeting, the board, the chairman of the board, board fees with a division between the chairman and other members of the board, auditors and fees to auditors and, where applicable, proposals for revising the principles for the appointment of the nomination committee.
The nomination committee for the 2025 AGM in Prolight Diagnostics AB (publ.) consists of chairman Jan Karlsson, who represents his own shares, appointed in accordance with the largest shareholders by number of votes. Other members are Paul Monaghan, who represents his own shares, appointed in accordance with the number of votes of the largest shareholders. Per-Anders Josenby, who represents Cardeon AB, appointed in accordance with the number of votes of the largest shareholders.
Shareholders who wish to submit proposals to the nomination committee can do so in writing to:
“Valberedningen”
Prolight Diagnostics AB (publ)
Gasverksgatan 3A
222 29 Lund
Sweden
Or by e-mail to:
valberedningen@prolightdx.com
